公开(公告)号：US09138486B2

公开(公告)日：2015-09-22

申请号：US14322262

申请日：2014-07-02

Applicant: PFIZER INC.

Inventor： Matthew David Doroski ,  Andreas Maderna ,  Christopher John O'Donnell ,  Chakrapani Subramanyam ,  Beth Vetelino ,  Russell George Dushin ,  Pavel Strop ,  Edmund Idris Graziani

IPC: A61K47/48 ,  A61K38/06 ,  A61K38/08 ,  A61K38/07 ,  C07K7/02 ,  C07K5/083 ,  C07K5/02 ,  C07K16/00

CPC classification number: C07K7/06 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6863 ,  A61K47/6889 ,  C07K5/0205 ,  C07K5/0808 ,  C07K7/02 ,  C07K16/00 ,  C07K2319/30

Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.

Abstract translation: 本发明涉及细胞毒性五肽，其抗体药物偶联物及其用于治疗癌症的方法。

公开(公告)号：US11993625B2

公开(公告)日：2024-05-28

申请号：US16477290

申请日：2018-01-10

Applicant: PFIZER INC.

Inventor： Omar Khaled Ahmad ,  Stephen Paul Brown ,  Kenneth John Dirico ,  Russell Dushin ,  Gary Frederick Filzen ,  Sujiet Puthenveetil ,  Pavel Strop ,  Chakrapani Subramanyam ,  Lawrence N. Tumey

IPC: C07H15/26 ,  A61K47/68 ,  A61P35/00 ,  A61K45/06

CPC classification number: C07H15/26 ,  A61K47/6807 ,  A61P35/00 ,  A61K45/06

Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.

公开(公告)号：US11814435B2

公开(公告)日：2023-11-14

申请号：US17005073

申请日：2020-08-27

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K31/454 ,  A61K31/69 ,  A61K31/704 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6801 ,  A61K47/6849 ,  C07K16/2803 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US10689458B2

公开(公告)日：2020-06-23

申请号：US15356750

申请日：2016-11-21

Applicant: Pfizer Inc.

Inventor： Dangshe Ma ,  Frank Loganzo, Jr. ,  Kimberly Ann Marquette ,  Edmund Idris Graziani ,  Puja Sapra ,  Pavel Strop

IPC: C07K16/32 ,  A61K47/68 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

公开(公告)号：US09175093B2

公开(公告)日：2015-11-03

申请号：US13857063

申请日：2013-04-04

Applicant: RINAT NEUROSCIENCE CORP. ,  PFIZER INC.

Inventor： Hong Liang ,  Yasmina Noubia Abdiche ,  Javier Fernando Chaparro Riggers ,  Bruce Charles Gomes ,  Julie Jia Li Hawkins ,  Jaume Pons ,  Xiayang Qiu ,  Pavel Strop ,  Yuli Wang

IPC: A61K39/395 ,  C07K16/40 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。